| Literature DB >> 30368889 |
Seyed Alireza Javadinia1, Soodabeh Shahidsales2, Azar Fanipakdel2, Mona Joudi-Mashhad2, Mehrane Mehramiz3, Sahar Talebian2, Mona Maftouh3, Ramin Mardani3, Seyed Mahdi Hassanian3, Majid Khazaei3, Gordon A Ferns4, Amir Avan3,5.
Abstract
The Wnt/β-catenin pathway is an important, dysregulated pathway in several tumor types, including pancreatic ductal adenocarcinoma. Although the activation of this pathway is an important component of normal development, its aberrant activation resulting from activating or inactivating mutations in the CTNNB1 gene locus, or in the negative regulators AXIN and APC involving stabilization of β-catenin, and activation of target genes leads to a more aggressive phenotype, suggesting its potential value as a therapeutic target in the treatment of pancreatic ductal adenocarcinoma. A number of small molecule and biologic agents have now been developed for targeting this pathway. This review summarizes the current knowledge about the therapeutic potential of targeting the Wnt pathway with particular emphasis on preclinical/clinical studies in the treatment of pancreatic ductal adenocarcinoma.Entities:
Keywords: Wnt signaling pathway; Wnt/ β-catenin; pancreas; therapeutic target; tumors
Year: 2018 PMID: 30368889 DOI: 10.1002/jcb.27835
Source DB: PubMed Journal: J Cell Biochem ISSN: 0730-2312 Impact factor: 4.429